Enabling Technologies
Page 1 to 16 of 103 |     NEXT PAGE >
New approaches to sample identification tracking and technologies for maintaining the quality of stored samples By Dr John Comley Summer 2017
Safeguarding the quality of stored samples (both compounds and biospecimens) must be the driving ethos in compound management stores and biorepositories. Yet there are few innovations in available sample storage technologies that can help them easily identify poor sample quality or monitor sample degradation and so minimise erroneous downstream analytical results.

Read More

Automated liquid handler vendor vs third party plastic company. by Dr John Comley Winter 16/17
Competing for the disposable pipette tip business.
Users of automated liquid handlers today invariably have a choice – obtain disposable pipette tips from the original instrument vendor or purchase a ‘compatible’ product from a third party plastics manufacturer or lab supplier.

Read More

3D cellular imaging - advances and considerations for high-content screening By O. Joseph Trask, Dr Daniel V. LaBarbera and Dr Kevin Quick Fall 16
Commercially available high-content imaging (HCI) systems, introduced in the 1990s, have provided the scientific community with a platform that offers a unique set of tools ideal for advancing high-throughput biological discoveries and therapeutic development.

Read More

CRISPR Cas9: transforming gene editing in drug discovery labs By Dr John Comley Fall 16
It is evident from a recent market survey on gene editing in drug discovery that CRISPR/Cas9 is now recognised as the superlative method when attempting a gene knockout or when introducing defined mutations, insertions or modifications to the genome.

Read More

Full length isoform sequencing yields a more comprehensive view of gene activity By Luke Hickey Fall 16
RNA-seq has revolutionised how scientists can interrogate gene expression. But after years of performing RNA-seq studies with short-read sequencers, many have realised that there is more to be discovered.

Read More

I, robot. I, the future Richard Holland Fall 16
The Pistoia Alliance, whose membership includes most of the world’s major pharmaceutical companies, technology vendors and publishers active in the life science R&D sector, is keenly interested in discovering the ways in which innovation through pre-competitive collaboration can be used to explore and exploit the constant stream of new technologies that become available.

Read More

With synthetic biology, drug discovery is going virtual. by Christopher Voigt Summer 2016
Christopher Voigt is a professor of biological engineering at the Massachusetts Institute of Technology, where his lab focuses on synthetic biology. Two major areas of interest for him are developing a genetic programming language for cells and applying synthetic biology to biotechnology challenges.

Read More

Metabolomics - a playbook for functional genomics By Dr D Ferrick Summer 2016
If we have learned anything from scientific research in the last 20 years, it is that finding cures to complex diseases is difficult. Despite the promise of the genomic revolution, disease progression and patient outcomes are still not easily predicted by genetic factors alone.

Read More

The coming of age of mass spectrometry imaging. By Dr Peter J.H. Webborn and Dr Richard J.A. Goodwin Spring 2016
Mapping complex drug distribution/retention in tissues, aligned with efficacy and safety biomarker localisation is now possible using label-free mass spectrometry imaging technologies.

Read More

Microtissues for in vitro toxicity assessment: Cost effective and in vivo relevant toxicology tools By Dr Stephanie Ravenscroft, Dr Caroline Bauch, Dr Laura Hinton and Dr Paul Walker Spring 2016
Conventional two-dimensional (2D) cell models (adherent cells grown on cell culture plates or cells in suspension) are limited in their abilities to accurately predict clinical toxicity since they lack the fundamental complexity of in vivo tissue environments.

Read More

Preclinical imaging: improving translational power in oncology. By Dr Todd Sasser Spring 2016
Imaging has long been indispensable in clinical practice, and researchers have for many years used the same toolbox of imaging modalities as a component of their preclinical and drug development work.

Read More

Seeing within: Magnetic Resonance Imaging in drug development. By Dr Geoff J.M. Parker Winter 2015/16
Magnetic Resonance Imaging (MRI) can be used to provide quantitative measurements in the form of imaging biomarkers. These measurements have a number of attractive characteristics: They are non-invasive, can provide organ and lesion localisation of morphology, physiology and metabolism and can be repeated over time.

Read More

New developments in single cell separation and analysis technologies. By Dr John Comley Drug Discovery Fall 2015
Recent advances of single cell technologies are facilitating the opportunity to discern biological insights within individual cells and providing a means to reveal previously hidden relationships between individual cells within a population.

Read More

Epigenetic Targets : on the verge of becoming a major new category for successful drug research. Summer 2015 By Dr John Comley
Most vendors of epigenetic modification proteins and reagents have enhanced and broadened their offerings in recent years. Of particular note is the increasing range of proteins and binding assays that now support research on the Bromodomains and other reader proteins.

Read More

Precise genome editing: the key to a CRISPR drug discovery pipeline? By Dr. J. D. Wrigley, Dr M Maresca, Dr K Birmingham, Dr M Bohlooly-Y and Dr L M. Mayr Spring 2015
From the pioneering days of Watson and Crick in 1953, to completion of the human genome project in 2003, advances in our understanding of DNA have raised hopes that its direct manipulation at the level of the genome could revolutionise the drug discovery process.

Read More

Enabling Technologies
Page 1 to 16 of 103 |     NEXT PAGE >